On the recordApril 6, 2014
This lack of predictability in the timing of DEA scheduling decisions leads to unnecessary uncertainty in the drug development process and needless delays in patients' access to new therapies.
Source
congress.govJoe Pitts: “This lack of predictability in the timing of DEA scheduling decisions leads to unnecessary uncertainty in the drug…”
Editor's note · Context
Highlighting issues with DEA scheduling affecting drug development.
Share
More from Joe Pitts
Jul 5, 2016
I urge support for this bipartisan bill, H.R. 5210. I yield back the balance of my time.
Jul 11, 2016
The recent events in Orlando, Paris and San Bernardino remind us of the very real threat of mass casualty events.
Sep 13, 2016
if they expanded Medicaid 50,000 of my constituents would have Medicaid, if the state expanded it.
Nov 14, 2016
I am very pleased to congratulate and welcome my good friend, Dwight Evans, to the floor of the House. Before I served here in Congress for the last 20 years, I served in the statehouse of Pennsylvania for 24 years. In the last 8 years of…
Other voices in this conversation
